Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nursing Shortage Eases With Recession's Help
"The nation"s deep recession is helping to alleviate the decade-long nursing shortage, as workers who had left the field in better times are returning in droves," the Wall Street Journal reports. The paper quotes a study, one of six papers on the nursing workforce published today in the journal Health Affairs, that found "nearly a quarter-million nurses entered the work force in 2007-08, an 18% surge that was the largest two-year increase in at least three decades." Many of them had left nursing, but "re-entered the work force to compensate for a spouse"s lost income or health benefits, the study said." The increase is "particularly remarkable at a time when the U.S. economy has shed more than six million jobs, helping to solidify the profession"s "recession-proof" image." The study found that the surge in new nurses is due to "efforts to expand nursing schools, attract more young people into the field and improve working conditions," along with an increase in the number of foreign-born nurses.

National Community Pharmacists Association Statement About House Democrats' Bill On Health Care Reform
U.S. House of Representative Democrats unveiled their bill for health care reform - the America"s Affordable Health Care Choice of 2009. In response, National Community Pharmacists Association (NCPA) Executive Vice President and CEO Bruce T. Roberts, RPh, issued the following statement:
News of the day
California Gov. Schwarzenegger's State Budget Plan Includes Cuts To County HIV/AIDS Services
The Santa Maria Times examines how California Gov. Arnold Schwarzenegger"s (R) plan to reduce state spending by more than $5 billion over the next two fiscal years, which includes millions of dollars in funding cuts to HIV prevention, education and treatment programs, could affect county residents (Womack, Santa Maria Times, 5/31). According to the Times, hundreds of residents in Santa Barbara County -- including more than 100 AIDS Drug Assistance Program (ADAP) clients -- would potentially be affected by the funding cuts (Santa Maria Times, 5/31). The proposal also would result in $1.8 million in cuts to programs for low-income residents living with HIV in Riverside County, the Desert Sun reports (Brambila, Desert Sun, 5/29). The plan, issued by Schwarzenegger last week, includes $55.5 million in cuts to California"s ADAP and other state Office of AIDS programs (Kaiser Daily HIV/AIDS Report, 5/27).
Nutrition

Management Change At Actelion - Isaac Kobrin To Take Newly Created Position Of Chief Medical Officer

Actelion Ltd (SIX: ATLN) announced the creation of the position of Chief Medical Officer (CMO). This change was initiated to fulfill the needs of a fast growing organization, which is developing products rapidly and managing a growing portfolio. Effective 1 July 2009, the current Head of Clinical Development, Isaac Kobrin will move into this position. He will continue to be a member of Actelion"s Executive Committee (AEC). As a consequence, Isaac will hand over his position as Head of Clinical Development to Guy Braunstein. Guy joins Actelion having served as Chief Medical Officer at Merck Serono and, before this, as Chief Medical Officer at Serono International. Guy will join Actelion"s Executive Committee adding his more than 20 years of experience to Actelion"s senior management decision-making committee. Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "With Isaac in this new position and the introduction of Guy to the Clinical Development team, we are increasing our focus on scientific and drug development expertise at Actelion. The sharing of this know-how across the functions of drug discovery, clinical development, registration and commercialization will ensure continued rapid advancement of our innovative compounds that will make a real difference to patients." Isaac Kobrin, Senior Vice President, Head of Clinical Development and Member of the Actelion Executive Committee commented: "I look forward to taking up this next challenge in my career with Actelion, knowing that the clinical development team will be in good hands with Guy. He brings an excellent understanding of what it takes to fully develop innovative compounds, providing physicians with evidence-based medicine. His arrival at Actelion will bring a fresh approach to our existing and future pipeline and I am sure that this collaborative approach will build on and advance our clinical capabilities." Guy Braunstein commented: "I am very excited to be joining Actelion where I have found energetic people who are committed to driving their compounds forward with a focus on the patient. The team I have met truly understands the importance of integrating science and medicine to offer potential therapies for these patients who are in desperate need of treatment. In this environment I feel we have an opportunity to really make a difference." About Guy Braunstein Guy Braunstein is a French citizen with an MD and is specialized in respiratory medicine. He has a PhD in life science. Guy joins Actelion from Merck Serono, where he was the Chief Medical Office, having served for 4 years before that as Chief Medical Officer at Serono International. His more than 20 years in the pharmaceutical industry spans a wide range of experience from affiliate Medical Director and Global Medical Affairs through to Research and Development roles. Guy has worked in both large pharmaceutical and biotech environments in companies such as Astra, Glaxo-Wellcome, GSK, Fisons, Rhç´ne-Poulenc Rorer and Chiron. During this time he built experience in multiple therapeutic areas, in particular respiratory, inflammation and autoimmune disorders, multiple sclerosis and oncology. About Isaac Kobrin Isaac Kobrin is an internist educated in Israel with further training (Fullbright Fellowship) at the Ochsner Medical Foundation in New Orleans, LA, USA, mainly in the cardiovascular and nephrology fields. He joined the clinical cardiovascular development department at F. Hoffmann-La Roche Ltd in 1989. During his 10 years at Roche he was responsible for the worldwide clinical development of key compounds within the company"s cardiovascular portfolio (from Phase 1 to marketing approval). In 1997 he became Group Leader of the cardiovascular development group. Isaac joined Actelion in September 1999 as Senior Vice President, Head of Clinical Development. Actelion Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009